ReviewPathogens (Basel, Switzerland)2020
Rifabutin for the Treatment of
Review in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Third-line and rescue therapy for refractoryWorld journal of gastroenterology · 2023Pooled it
- Levofloxacin and Rifampin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies forThe Lancet regional health. Western Pacific · 2026Article
- Superior Efficacy of Bismuth-Containing Rifabutin Quadruple Therapy over Rifabutin Triple Therapy as Salvage Treatment.Gut and liver · 2026Article
- VTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2026Article
- A Review on the Progress and Strategies ofGastroenterology research and practice · 2026Review
- Whole genome sequence analysis ofiScience · 2025Article
- Repurposing antibiotics: A dual-action approach against bacteria-induced cancer.Cancer pathogenesis and therapy · 2025Review
- Article
- Diagnosis and treatment ofFuture microbiology · 2025Review
- Towards EffectiveInternational journal of molecular sciences · 2025Review
- Do the new ACGJournal of the Canadian Association of Gastroenterology · 2025Article
- Therapeutic advances and future directions inFrontiers in microbiology · 2025Review
- Beyond antibiotics: probiotics as a promising ally againstFrontiers in pharmacology · 2025Review
- Antibiotic Susceptibility-Guided Concomitant Therapy Regimen with Vonoprazan, High-Dose Amoxicillin, Clarithromycin, and Metronidazole forMicroorganisms · 2024Article
- Single-Arm, Prospective, Interventional Study ofJournal of clinical medicine · 2024Article
- Current and Future Perspectives on the Management ofAntibiotics (Basel, Switzerland) · 2024Review
- Change in Diagnosis ofAntibiotics (Basel, Switzerland) · 2024Review
- Rifabutin: a repurposed antibiotic with high potential against planktonic and biofilm staphylococcal clinical isolates.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays, apart from having to know first-line
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.